Skip to content

Effect of intravenous lidocaine on hypoxemia during bronchoscopic surgery under general anesthesia: a randomized controlled trial

Effect of intravenous lidocaine on hypoxemia during bronchoscopic surgery under general anesthesia: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079933
Enrollment
Unknown
Registered
2024-01-16
Start date
2024-01-18
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypoxemia

Interventions

lidocaine group:Lidocaine 1.5 mg/kg was injected intravenously and continued at a rate of 2 mg/kg/h until the end of the procedure
control group:The same volume of normal saline was injected intravenously, and the same amount of normal saline was continued during the operation until the end of the operation.

Sponsors

The Third Affiliated Hospital of Shandong First Medical University(Affiliated Hospital of Shandong Academy of Medical Sciences)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-70 years old,18<BMI < 28 Kg/?; 2. ASA is graded from ? to ?; 3. Patients who intend to undergo bronchoscopic surgery under general anesthesia (endoscopic biopsy and/or brush examination, alveolar perfusion, Ebus-TBNA, Ebus-TBLB, endoscopic resection of airway lesions); 4. The informed consent for the study has been signed;

Exclusion criteria

Exclusion criteria: 1.severe cardiopulmonary dysfunction, such as hypoxemia (resting state SPO2< 90%), chronic arrhythmias (HR< 50/min), hypotension (MAP< 60 mmHg), New York Heart Association (NYHA) classification =?, history of conduction block, etc. 2. Exacerbation of COPD or recent acute upper respiratory tract infection; 3. Pregnancy or lactation; 4. Preoperative cognitive dysfunction; 5. Abnormal liver and kidney function; 6. Allergic to narcotic drugs and opioids; 7. Use of local anesthetics in the past 24 hours; 8. Participated in other clinical studies within three months.

Design outcomes

Primary

MeasureTime frame
Spo2;

Secondary

MeasureTime frame
interleukin-6;interleukin-8;Changes in hemodynamics;Coughing frequency;Adverse event occurrence rate;

Countries

China

Contacts

Public ContactZhang Qian

The Third Affiliated Hospital of Shandong First Medical University(Affiliated Hospital of Shandong Academy of Medical Sciences)

tianshiibelieve@126.com+86 156 6273 2375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026